Last reviewed · How we verify
NCT04177056: SOLAR-P
Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief
NA trial testing SBRT in Bone Metastases in 40 participants. Status unknown.
1 March 2022
Quick facts
| Lead sponsor | Hamilton Health Sciences Corporation |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 4 December 2020 |
| Primary completion | 1 March 2022 |
| Estimated completion | 1 January 2023 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- SBRT — full drug profile →
Conditions studied
- Bone Metastases — all drugs for Bone Metastases →
- Prostate Cancer — all drugs for Prostate Cancer →
- Breast Cancer — all drugs for Breast Cancer →
- Renal Cell Carcinoma — all drugs for Renal Cell Carcinoma →
Sponsor
Hamilton Health Sciences Corporation — full company profile →
Who can join
18 and older, any sex, with Bone Metastases or Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Radiation therapy has been shown to be very effective at relieving pain caused by bone metastases. However, certain types of cancers such as prostate, breast, kidney, and melanoma can have resistance to radiation, making treatment less successful. Stereotactic body radiotherapy (SBRT) is a newer form of focused treatment that gives higher doses of radiation without damage to surrounding organs. It often is used to help control and cure disease, but less commonly as a way to palliate and treat symptoms. This study is looking at using SBRT for the purposes of improving pain caused by bone metastases in prostate cancer, breast cancer, kidney cancer, and melanoma patients. It is theorized that the higher levels of radiation may be able to combat the resistance some tumour cells have to radiotherapy and provide improved pain response to treatment. The investigators are looking to show that SBRT has a role in helping this group of patients deal with painful bone lesions from their cancer without increasing side effects and toxicity from the radiation treatment.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Beyond the Knife in Renal Cell Carcinoma: A Systematic Review-To Ablate or Not to Ablate?
Green H, Taylor A, Khoo V. · · 2023 · cited 9× · PMID 37444565 · DOI 10.3390/cancers15133455 -
Stereotactic body radiotherapy for osseous low alpha-beta resistant metastases for pain relief-SOLAR-P.
Nguyen EK, Quan K, Parpia S, Tran S, et al · · 2021 · PMID 34479581 · DOI 10.1186/s13014-021-01897-0
Verify or expand the search:
- PubMed search for NCT04177056
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SBRT
Trials testing the same drug.
- NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
- NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
- NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
- NCT07451795 — SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC · Phase 2 · recruiting
- NCT07410234 — Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity · Phase 2 · not yet recruiting
Other recruiting trials for Bone Metastases
Currently open trials in the same condition.
- NCT06713941 — Management of Bone Metastases · active not recruiting
- NCT06392217 — clinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone Metastases · recruiting
- NCT06065449 — A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT) vs Conventional Palliative Radiation T · Phase 3 · recruiting
- NCT06487013 — Effectiveness and Safety of ArcBlate Palliative Treatment for Patients With Painful Bone Metastases: A Pivotal Study · NA · recruiting
- NCT06189079 — Arterial Embolization for the Treatment of Bone Metastases: Prospective Observational Study · recruiting
Other Hamilton Health Sciences Corporation trials
Trials by the same sponsor.
- NCT06567808 — Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial · Phase 4 · not yet recruiting
- NCT07118696 — Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease · Phase 3 · not yet recruiting
- NCT07027436 — Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Su · Phase 3 · not yet recruiting
- NCT06908694 — Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy · Phase 4 · recruiting
- NCT06836024 — A Trial of Actazin Versus PEG 3350 for Maintenance Therapy in Children With Constipation · Phase 2, PHASE3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04177056 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hamilton Health Sciences Corporation
- Last refreshed: 2 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04177056.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing